JNJ Johnson & Johnson
USHealthcareAs of 2026-08-24
Why JNJ matters now
Johnson & Johnson (JNJ) is a US stock in Healthcare. The latest InvestLog snapshot shows $273.03 with +1.03% on the session and $657.97B in market capitalization; recent performance reads 1-month -0.70% and YTD +10.36%.
The latest financial table shown here is Q1 2026, with revenue of $24.06B, net income of $5.24B, and EPS of $2.14. Investors can compare that operating picture with valuation signals such as P/E 21.44 and FCF yield 3.2%.
InvestLog's latest related AI research is a Material Company Event note titled "JNJ regulatory decision: FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients". The latest indexable market news headline is "Louisiana Jury Issues $10 Million Verdict in Talc-Related Mesothelioma Case Against Johnson & Johnson" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $255.00; recent insider activity includes Wengel Kathryn E filing M-Exempt; recent congressional disclosure data includes Ro Khanna Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
21.44
PEG
0.24
P/B
6.88
P/S
5.71
EV/EBITDA
17.41
DCF Value
$326.99
FCF Yield
3.2%
Div Yield
2.3%
Margins & Returns
Gross Margin
69.1%
Operating Margin
26.9%
Net Margin
21.8%
ROE
26.3%
ROA
10.5%
ROIC
13.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $24.06B | $5.24B | $2.14 |
| Q1 2026 | $24.06B | $5.24B | $2.14 |
| Q4 2025 | $24.56B | $5.12B | $2.10 |
| FY 2025 | $94.19B | $26.80B | $11.03 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$251.55
Target (Median)
$255.00
Target Range
$208.00 - $283.00
Trading Activity
Insider Trades
Congress Trades
Related AI Research
JNJ regulatory decision: FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patientsJohnson & Johnson（JNJ）的 产品 获美国 FDA 许可或批准
JNJ regulatory decision: FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients.Johnson & Johnson（JNJ）的 产品 获美国 FDA 许可或批准。PR Newswire 于 2026-08-24 发布该事件。
Duato Joaquin sells $32.2M of JNJDuato Joaquin 内部减持 强生 (JNJ) $32.2M
Johnson & Johnson (JNJ) CEO and Chairman Duato Joaquin completed an open-market sale of 123,291 company shares on August 13, 2026, for total proceeds of $32,199,927 at an average per-share price of.强生（JNJ）首席执行官兼董事长Duato Joaquin于2026年8月13日完成123,291股公司股票的公开市场出售，交易总价值32,199,927美元，对应每股均价261.17美元。该笔交易于2026年8月14日通过Form 4文件向美国SEC提交，属于强制披露的高管持股变动信息，为市场参与者提供了核心管理层的公开交易记录。
JOHNSON & JOHNSON files 8-K Item 5.02 executive-change disclosure强生 (JNJ) 提交 8-K Item 5.02 高管变动披露
On August 4, 2026, Johnson & Johnson (NYSE: JNJ) filed an 8-K form with the U.S. Securities and Exchange Commission (SEC filing link: Per Item 5.2026年8月4日，强生（NYSE: JNJ）向美国SEC提交8-K备案文件（备案链接： Taubert将于2026年9月1日正式退休，相关新闻稿作为附件99.1附于本次备案中。Taubert负责强生两大核心业务板块之一的创新医药板块，该板块2026年二季度实现营收253.1亿美元，超出市场预期约2477万美元。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US
Exchange
—
Beta
0.26
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.